241
Participants
Start Date
July 25, 2017
Primary Completion Date
February 27, 2018
Study Completion Date
February 27, 2018
Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution
Vehicle of DE-126 Ophthalmic Solution dosed once daily for 6weeks, followed by high dose of DE-126 dosed once daily for 6 additional weeks
Topical ultra-low dose of DE-126 Ophthalmic Solution
Topical ultra-low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
Topical low dose of DE-126 Ophthalmic Solution
Topical low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
Topical medium dose of DE-126 Ophthalmic Solution
Topical medium dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
Topical high dose of DE-126 Ophthalmic Solution
Topical high dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
0.005% Latanoprost Ophthalmic Solution
0.005% Latanoprost Ophthalmic Solution dosed once daily for 12 weeks
Rochester Ophthalmological Group, PC, Rochester
Cornerstone Health Care, LLC, High Point
Mundorf Eye Center, Charlotte
Coastal Research Associates, LLC, Roswell
Clayton Eye Clinical Research, LLC, Morrow
Shettle Eye Research, Inc., Largo
Keystone Research LTD SMO/Medical Center Ophthalmology Assoc., San Antonio
Keystone Research Ltd SMO/Texan Eye, PA, Austin
Sall Research Medical Center, Inc, Artesia
North Valley Eye Medical Group, Mission Hills
Eye Research Foundation, INC, Newport Beach
North Bay Eye Associates, Inc., Petaluma
Murakami Karindoh Hospital, Fukuoka-shi, Fukuoka
Nagasaka Eye Clinic, Nagoya-shi, Aichi
Sugiura Eye Clinic, Osaka-shi, Osaka
Sapporo Katoh Ophthalmology Clinic, Sapporo-shi, Hokkaido
Dogenzaka Kato Eye Clinic, Shibuya-ku, Tokyo
Santen Inc.
INDUSTRY